Cantor Fitzgerald Keeps Their Buy Rating on Bausch Health Companies Inc (BHC)


Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Bausch Health Companies Inc (NYSE: BHC) today and set a price target of $32. The company’s shares closed yesterday at $20.67.

Chen observed:

“We rate BHC as 12-month price target of $32. A greater appreciation for BHC’s solid execution and future growth prospects under the new management team should drive upwards earnings revisions in 2019+, multiple expansion, and BHC shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $32.”

According to TipRanks.com, Chen ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.2% and a 40.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals Inc, Melinta Therapeutics Inc, and Aclaris Therapeutics Inc.

Currently, the analyst consensus on Bausch Health Companies Inc is a Hold with an average price target of $23.86.

See today’s analyst top recommended stocks >>

The company has a one-year high of $27.79 and a one-year low of $10.94. Currently, Bausch Health Companies Inc has an average volume of 6.73M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts